For the Management of
MTX Toxicity

Exceptional Circumstances means that due to the rarity of the disease and for ethical reasons it has not been possible to obtain complete information on this medicinal
product. The European Medicine Agency will review any new information which may become available every year and this
Summary of Product Characteristics (SmPC) will be updated as necessary.

Voraxaze^® is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination.⁴
▼This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.